Investors are Trading These Healthcare Stocks Ahead of Earnings

Hospira, Inc. (NYSE:HSP) will unveil its latest earnings on Tuesday, February 14, 2012. The average estimate of analysts is for profit of 45 cents per share, a decline of 41.6% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 47 cents. Between one and three months ago, the average estimate was unchanged. It has since dropped over the last month. Analysts are projecting profit to rise by 9.7% versus last year to $2.99.

The company met estimates last quarter after beating the forecasts in the prior two. In the third quarter, the company reported net income of 66 cents per share versus a mean estimate of profit of 66 cents per share. In the second quarter, the company beat estimates by 16 cents. Analysts are projecting a decline of 4.6% in revenue from the year-earlier quarter to $946.4 million.

Competitors to Watch: Teva Pharmaceutical Industries Ltd(NASDAQ:TEVA), Mylan Inc. (NASDAQ:MYL), Akorn, Inc. (NASDAQ:AKRX), Novartis AG (NYSE:NVS), Baxter International Inc. (NYSE:BAX), Watson Pharmaceuticals, Inc. (NYSE:WPI), Pfizer Inc. (NYSE:PFE), DURECT Corporation (NASDAQ:DRRX), ICU Medical, Incorporated (NASDAQ:ICUI), and Allergan, Inc. (NYSE:AGN).

Watson Pharmaceuticals, Inc. (NYSE:WPI) will unveil its latest earnings on Tuesday, February 14, 2012. The average estimate of analysts is for net income of $1.75 per share, a rise of 88.2% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from $1.61. Between one and three months ago, the average estimate was unchanged. It has risen during the last month. For the year, analysts are projecting profit of $4.76 per share, a rise of 46.9% from last year.

Last quarter, the company reported net income of $1.09 per share versus a mean estimate of profit of. The company has beaten estimates for the past three quarters. On average, analysts predict $1.54 billion in revenue this quarter, a rise of 61.6% from the year ago quarter. Analysts are forecasting total revenue of $4.58 billion for the year, a rise of 28.3% from last year’s revenue of $3.57 billion.

Competitors to Watch: Mylan Inc. (NASDAQ:MYL), Novartis AG (NYSE:NVS), Par Pharmaceutical Companies, Inc. (NYSE:PRX), Pfizer Inc. (NYSE:PFE), Impax Laboratories, Inc. (NASDAQ:IPXL), Lannett Company, Inc. (AMEX:LCI), Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA), Columbia Laboratories Inc. (NASDAQ:CBRX), Perrigo Company (NASDAQ:PRGO), and Johnson & Johnson (NYSE:JNJ).

To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com